Eli Lilly & Co. 1997 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 1997. Eli Lilly and Company operates in a single industry segment: Life Sciences. The Company discovers, develops, manufactures, and sells pharmaceutical products, animal health products, and provides health care management services through its subsidiaries PCS HealthSystems and Integrated Medical Systems (IMS). Products are sold in approximately 160 countries, with manufacturing facilities in the U.S., Puerto Rico, and 27 other nations.
Key Financial Metrics
Note: Specific revenue, net income, cash flow, and debt figures are incorporated by reference from the 1997 Annual Report (Exhibit 13) and are not explicitly stated in the provided text. The following metrics are available from the filing text:
- Research & Development (R&D) Expenditures: $1.38 billion in 1997 (up from $1.19 billion in 1996 and $1.04 billion in 1995).
- Royalties Paid: Approximately $140 million in 1997.
- Royalties Received: Not material.
- Market Capitalization: Aggregate market value of voting stock held by non-affiliates was $59,637,592,293 as of February 13, 1998.
- Shares Outstanding: 1,111,258,506 shares of common stock as of February 13, 1998.
- Employee Count: Approximately 31,100 employees at year-end 1997 (15,100 outside the U.S.).
- R&D Personnel: Approximately 5,750 people engaged in pharmaceutical and animal health R&D.
Material Changes and Operational Highlights
- Product Launches: Evista (osteoporosis prevention) was cleared for marketing in late 1997 and launched in early 1998. Zyprexa (schizophrenia) and Gemzar (cancer) are highlighted as major products.
- Strategic Joint Venture: In March 1998, the Company formed Kinetra, a joint venture with Electronic Data Systems (EDS), to develop an electronic health information network. IMS operations will become part of Kinetra (49% owned by Lilly, 51% by EDS).
- Marketing Shifts: The Company began direct-to-consumer advertising in the U.S. in 1997. Five wholesale distributors accounted for approximately 55% of consolidated net sales in 1997.
- Patent Expirations: The U.S. compound patent for Prozac expires in 2001, with a process patent expiring in 2003. Other key expirations include Axid (2002), Lorabid (2006), and Gemzar (2006).
Outlook, Risks, and Contingencies
Legal Proceedings:
- Prozac Patent Litigation: The Company is defending its patents against challenges by Barr Laboratories and Geneva Pharmaceuticals, who allege invalidity. An unfavorable outcome could materially adversely affect financial position and liquidity.
- Pricing Litigation: The Company is a defendant in numerous antitrust and pricing cases (e.g., Robinson-Patman Act) brought by retail pharmacies and consumers. A Federal Class Action settlement was reached and accrued in 1995 (amount not material). Other state and federal cases remain pending.
- Product Liability: Approximately 170 actions involve DES (diethylstilbestrol) and 15 actions involve Prozac.
- Regulatory Investigations: The FTC is conducting non-public investigations into the Company's pricing practices and the relationship between the Company and its PBM subsidiary, PCS.
Risks and Outlook:
- Competition: Intense competition from generic manufacturers upon patent expiration and from new branded products. Managed care organizations are intensifying price competition.
- Regulatory Environment: Extensive government regulation regarding product approval, pricing, and advertising. Cost containment measures (rebates, price controls) are expected to continue globally.
- Foreign Operations: Risks include currency fluctuations, local restrictions on fund transfers, and weak patent protection in some countries.
Investor Verification Checklist
- Verify the specific consolidated net sales, net income, and cash flow figures in the 1997 Annual Report (Exhibit 13), as they are incorporated by reference in this filing.
- Monitor the status of the Prozac patent litigation against Barr and Geneva, given the 2001 compound patent expiration.
- Review the FTC investigations regarding pricing practices and the PCS consent decree for potential future liabilities.
- Assess the impact of the Kinetra joint venture on the future of the IMS business unit.
- Track the commercial performance of new launches, specifically Evista and Zyprexa, to offset potential revenue declines from patent expirations.